Abstract
Adrenomedullin (ADM) is a 52-amino acid peptide with structural homology to calcitonin generelated peptide (CGRP) initially isolated from human pheochromocytoma. ADM is synthesized and is secreted from many mammalian tissues, including the adrenal medulla, endothelial and vascular smooth muscle cells, as well as the myocardium and central nervous system. ADM has been implicated as a mediator of several diseases such as cardiovascular and renal disorders, sepsis, inflammation, diabetes and cancer. ADM is also expressed in a variety of tumors, including breast, endometrial and prostate cancer. ADM has been shown to be a mitogenic factor capable of stimulating growth of several cancer cell types. In addition, ADM is a survival factor for certain cancer cells and an indirect suppressor of the immune response. ADM plays an important role in environments subjected to low oxygen tension, which is a typical feature of solid tumors. Under these conditions, ADM is up regulated and acts as a potent angiogenic factor promoting neovascularization. The major focus of this review will be on the role of ADM in cancer, with emphasis on its utility in diagnostic and prognostic terms, along with its relevance as a therapeutic target.
Keywords: Adrenomedullin, tumor, progression, angiogenesis, hypoxia
Current Cancer Drug Targets
Title: Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Volume: 6 Issue: 7
Author(s): Misa Nakamura, Bo Han, Osamu Nunobiki and Kennichi Kakudo
Affiliation:
Keywords: Adrenomedullin, tumor, progression, angiogenesis, hypoxia
Abstract: Adrenomedullin (ADM) is a 52-amino acid peptide with structural homology to calcitonin generelated peptide (CGRP) initially isolated from human pheochromocytoma. ADM is synthesized and is secreted from many mammalian tissues, including the adrenal medulla, endothelial and vascular smooth muscle cells, as well as the myocardium and central nervous system. ADM has been implicated as a mediator of several diseases such as cardiovascular and renal disorders, sepsis, inflammation, diabetes and cancer. ADM is also expressed in a variety of tumors, including breast, endometrial and prostate cancer. ADM has been shown to be a mitogenic factor capable of stimulating growth of several cancer cell types. In addition, ADM is a survival factor for certain cancer cells and an indirect suppressor of the immune response. ADM plays an important role in environments subjected to low oxygen tension, which is a typical feature of solid tumors. Under these conditions, ADM is up regulated and acts as a potent angiogenic factor promoting neovascularization. The major focus of this review will be on the role of ADM in cancer, with emphasis on its utility in diagnostic and prognostic terms, along with its relevance as a therapeutic target.
Export Options
About this article
Cite this article as:
Nakamura Misa, Han Bo, Nunobiki Osamu and Kakudo Kennichi, Adrenomedullin: A Tumor Progression Factor via Angiogenic Control, Current Cancer Drug Targets 2006; 6 (7) . https://dx.doi.org/10.2174/156800906778742442
DOI https://dx.doi.org/10.2174/156800906778742442 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iodine in Mammary and Prostate Pathologies
Current Chemical Biology In vivo Cancer Imaging with Semiconductor Quantum Dots
Current Pharmaceutical Analysis The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Design and Synthesis of 3,4-diarylpyrrole Analogues as Potent Topoisomerase Inhibitors
Medicinal Chemistry LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry In Silico Bioisosteric Replacements of hnRNP K Ligands as Anticancer Lead Compounds
Current Physical Chemistry The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Synthesis and Antiproliferative Activity of 2-arylidene 6-(2-aryl-2-oxoethoxy)Benzofuran-3-one Derivatives
Letters in Drug Design & Discovery Editorial
Current Metabolomics Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Development of a Web-Enabled SVR-Based Machine Learning Platform and its Application on Modeling Transgene Expression Activity of Aminoglycoside-Derived Polycations
Combinatorial Chemistry & High Throughput Screening Pathogen-Related Signal Transduction Pathways of Dendritic Cells: Perspectives for Cancer Immunotherapy
Current Signal Transduction Therapy